Patents Assigned to City of Hope
-
Publication number: 20230166004Abstract: A two-dimensional lattice or mesh scaffold for therapeutic cell implants is disclosed as well as methods for manufacture and use. The lattice is constructed of crisscrossing capillaries of hydrophobic parylene, such as parylene AF4, that may be coated with a hydrophilic polymer, such as parylene C, for cell adhesion. At each intersection of the crisscross, the intersecting capillaries are internally connected so as to allow oxygen to flow freely within. The walls of the capillaries are thin enough to be permeable to oxygen, on the scale of a micron thick, so that oxygen can flow through the lattice and permeate through the capillary walls. For some implants, cells are sandwiched between two or more lattices, the cells being slightly held apart from aggregation with each other by the lattice holes. The implants may then be surgically implanted within a subject.Type: ApplicationFiled: November 28, 2022Publication date: June 1, 2023Applicants: California Institute of Technology, City of HopeInventors: Yu-Chong Tai, Kuang-Ming Shang, Hirotake Komatsu
-
Patent number: 11661463Abstract: Provided herein are cell penetrating conjugates. The conjugates include non-cell penetrating proteins connected through a phosphorothioate nucleic acid, wherein the phosphorothioate nucleic acid enhances intracellular delivery of the non-cell penetrating proteins. Also provided are methods and kits including the conjugates provided herein.Type: GrantFiled: August 5, 2016Date of Patent: May 30, 2023Assignee: City of HopeInventors: Andreas Herrmann, Hua Yu
-
Patent number: 11660098Abstract: A hand tool has a pivot connection pivotally attaching a first arm to a second arm, with the pivot connection fixed relative to the first arm and movable to first and second positions relative to the second arm. A spring urges the pivot connection into the first position. When jaws on the front ends of the arms clamp tissue with force greater than a pre-set threshold, the spring force is overcome and the jaws may move linearly apart, allowing for more uniform clamping of the tissue. The first arm may have an arm spring extending between a front segment pivotally attached to a rear segment of the first arm.Type: GrantFiled: September 25, 2020Date of Patent: May 30, 2023Assignee: City of HopeInventor: Gagandeep Singh
-
Publication number: 20230159626Abstract: Disclosed herein are antibodies or immunogenic fragments thereof that specifically bind to Epstein-Barr virus (EBV) glycoprotein 350 (gp350) or 220 or one or more epitopes of EBV gp350 and neutralize EBV infection. Also disclosed are immunogenic peptides comprising one or more gp350 epitopes, EBV antibody-small molecule conjugates and pharmaceutical compositions comprising the antibody or an immunogenic fragment thereof, one or more epitopes of EBV gp350, one or more immunogenic peptides, or the EBV antibody-small molecule conjugate. The antibodies, epitopes, immunogenic peptides, conjugates, and pharmaceutical compositions can be used to treat or prevent EBV infections and EBV-associated conditions and diseases.Type: ApplicationFiled: July 29, 2022Publication date: May 25, 2023Applicants: CITY OF HOPE, CALIFORNIA INSTITUTE OF TECHNOLOGYInventors: Javier Gordon OGEMBO, Lorraine Zvichapera MUTSVUNGUMA, Alison Evelynn ONDRUS
-
Patent number: 11646099Abstract: In embodiments of the invention, the invention provides a method for distinguishing between lymphoma types based on gene expression measurements. In embodiments, the invention distinguishes between PMBCL and DLBCL based on gene expression signatures, and can further distinguish between DLBCL subtypes. In embodiments of the invention, the distinctions are used in methods of treatment.Type: GrantFiled: December 13, 2019Date of Patent: May 9, 2023Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, British Columbia Cancer Agency, Mayo Foundation for Medical Education and Research, Julius-Maximilians-University of Würzburg, Boatd of Regents of the University of Nebraska, Oslo University Hospital HF, Hospital Clinic de Barcelona, Universitat de Barceloa, Institut D'Investigacions Biomédiques Pi I Sunyer (IDIBAPS), Robert Bosch Gesellschaft feuer medizinische Forshung mbH, Oregon Health & Science University, City of Hope, The Cleveland Clinic FoundationInventors: Louis M. Staudt, Christian Steidl, Anja Mottok, George W. Wright, David William Scott, Lisa M. Rimsza, Andreas Rosenwald, Randy Gascoyne, Timothy Greiner, Dennis Weisenburger, Erlend B. Smeland, Jan Delabie, Elias Campo Guerri, German Ott, Rita Braziel, Elaine S. Jaffe, Kai Fu, Wing C. Chan, Joo Song, James R. Cook
-
Patent number: 11643655Abstract: Disclosed herein are methods and compositions for enhancing gene targeting. The method entails co-administrating to a cell a targeting molecule and a means of enhancing the function of the targeting molecule upon delivery to the cell. The means of enhancing the function of the targeting molecule including one or more of a stressor that induces cellular stress, a proton sponge molecule, and an endosome or lysosome inhibitor. Compositions disclosed include a targeting molecule and one or more of a stressor that induces cellular stress, a proton sponge molecule, and an endosome or lysosome inhibitor.Type: GrantFiled: November 15, 2017Date of Patent: May 9, 2023Assignee: CITY OF HOPEInventors: Daniela Castanotto, Cy Stein, Xiaowei Zhang
-
Patent number: 11643659Abstract: Disclosed herein are conditional siRNAs activatable by CBF?-MYH11 oncogenic gene and use thereof for treating conditions such as acute myeloid leukemia (AML). The conditional siRNAs target MCL-1 or HDAC8.Type: GrantFiled: February 10, 2020Date of Patent: May 9, 2023Assignees: CITY OF HOPE, CALIFORNIA INSTITUTE OF TECHNOLOGYInventors: Guido Marcucci, Ya-Huei Kuo, Si-ping Han, Lisa Scherer, William A. Goddard, III, John Rossi
-
Publication number: 20230137548Abstract: Provided are methods and compositions for treating cancer with a combination of neural stem cells (NSCs) and an oncolytic virus or a combination of oncolytic virotherapy and immune modulation. The method entails administrating to a subject a pharmaceutical composition comprising a combination of NSCs and an oncolytic virus, and/or NSCs packaged with one or more immunomodulatory viruses expressing one or more immunity checkpoint inhibitors, including adaptive immunity checkpoint inhibitors and innate immunity checkpoint inhibitors. The immunity checkpoint inhibitors include shRNAs against the immunity checkpoint proteins. The cancer includes but is not limited to primary, recurrent, and metastatic brain cancer, breast cancer, head and neck cancer, bladder cancer, ovarian cancer, uterine cancer, prostate cancer, skin cancer, lung cancer, and colorectal cancer.Type: ApplicationFiled: July 11, 2022Publication date: May 4, 2023Applicant: CITY OF HOPEInventors: Alexandra Jacqueline ANNALA, Karen ABOODY, Jennifer COVELLO, Rachael MOONEY
-
Publication number: 20230140549Abstract: An expression system for expressing a herpesvirus glycoprotein complex including a vector inserted with two or more nucleic acid sequences that encode two or more subunits of a herpesvirus glycoprotein complex linked by one or more linking sequences such that the subunits are co-expressed simultaneously and self-processed to assemble into a glycoprotein complex. The expression system or the vector can be included in a vaccine composition. The vaccine composition can be used for preventing or treating herpesvirus infections.Type: ApplicationFiled: June 9, 2022Publication date: May 4, 2023Applicant: CITY OF HOPEInventors: Felix WUSSOW, Don J. DIAMOND
-
Publication number: 20230107117Abstract: Disclosed herein are conditional siRNAs activatable by pro-hypertrophic RNA sequences and use thereof for treating conditions such as cardiac hypertrophy. The conditional siRNAs target calcineurin or HDAC2.Type: ApplicationFiled: August 10, 2018Publication date: April 6, 2023Applicants: CITY OF HOPE, CALIFORNIA INSTITUTE OF TECHNOLOGY, THE GENERAL HOSPITAL CORPORATIONInventors: Saumya DAS, Ane Miren SALVADOR GARICANO, Si-ping HAN, Lisa SCHERER, Julia DEROGATIS, Robin HU, Sahil SAGAR, William A. GODDARD, III, John ROSSI
-
Patent number: 11618780Abstract: Provided are compositions and methods for activating latent Human Immunodeficiency Virus (HIV). The compositions and methods may utilize a recombinant peptide that has a DNA binding zinc finger domain specific to the HIV long terminal repeat (LTR) sequence. The recombinant peptide may also have a transcription factor (e.g. a transcription activator) that is conjugated to the zinc finger domain. Also provided are methods of treating HIV in a subject in need of the treatment. The method may involve activation of latent HIV in cells of the subject and selectively removing such cells from the subject, providing complete and effective treatment of HIV.Type: GrantFiled: October 22, 2018Date of Patent: April 4, 2023Assignee: CITY OF HOPEInventors: Kevin V. Morris, Marc S. Weinberg, Tristan Scott, Daniel Lazar
-
Publication number: 20230097513Abstract: Disclosed are methods of producing poxvirus-based vectors or recombinant poxvirus-based vectors from naturally derived, chemically synthesized DNA fragments, or a combination of naturally derived and chemically synthesized DNA fragments. One or more DNA sequences encoding one or more antigens, subunits or fragments thereof or other heterologous gene sequences are inserted in one or more poxvirus insertion sites in one or more DNA fragments. The methods include transfecting a host cell with one or more circular or linear DNA fragments such that a poxvirus or recombinant poxvirus is reconstituted in the host cell, the reconstituted poxvirus or recombinant poxvirus comprising the genome of a desired poxvirus. Also disclosed are poxviruses or recombinant poxviruses produced by the technology and uses thereof.Type: ApplicationFiled: February 2, 2021Publication date: March 30, 2023Applicant: CITY OF HOPEInventors: Don J. DIAMOND, Felix WUSSOW
-
Patent number: 11607184Abstract: Systems and methods relate to multi-modal imaging of tissue combined with highly focused radiation interventions. The system is a portable multimodal imaging unit that integrates imaging and image analysis. The system can be retrofitted to use with any commercial radiation therapy machine. In one aspect, a system integrates various imaging modalities into a single, coordinated structure. The system integrates X-ray and cone beam computed tomography (CBCT), optical imaging (such as bioluminescent imaging (BLI), fluorescence tomography (FT)), and positron emission tomography (PET) imaging in a single, self-contained structure.Type: GrantFiled: May 28, 2020Date of Patent: March 21, 2023Assignees: City of Hope, The Regents of the University of CaliforniaInventors: Susanta K. Hui, Gultekin Gulsen, Farouk Nouizi
-
Patent number: 11607457Abstract: Provided herein are, inter alia, nucleic acid-peptide conjugates including a non-cell penetrating protein (e.g., an Hdm2 targeting peptide) attached at its C-terminus to a phosphorothioate nucleic acid. Attachment of the phosphorothioate nucleic acid to the non-cell penetrating protein conveys stability to and allows for efficient intracellular delivery of the non-cell penetrating peptide. The nucleic acid-peptide conjugates provided herein including embodiments thereof are useful, inter alia, for the treatment of cancer.Type: GrantFiled: July 13, 2018Date of Patent: March 21, 2023Assignees: CITY OF HOPE, SORRENTO THERAPEUTICS, INC.Inventors: Andreas Herrmann, Hua Yu, Yanwen Fu
-
Patent number: 11602554Abstract: The disclosure provides, inter alia, methods and materials involved in treating cancer using a p53 vaccine in combination with a PD-1 pathway inhibitor.Type: GrantFiled: December 8, 2017Date of Patent: March 14, 2023Assignee: CITY OF HOPEInventor: Don J. Diamond
-
Patent number: 11604185Abstract: Provided herein is a large immuno-sorbent surface area assay (ALISSA) for the rapid and sensitive detection of botulinum neurotoxins (BoNTs) and anthrax toxin. This assay is designed to capture a low number of toxin molecules and to measure their intrinsic protease activity via conversion of a fluorogenic or luminescent substrate. Also provided herein are novel peptides that can be specifically cleaved by BoNT and novel peptides that are resistant to cleavage by BoNT. The combination of these cleavable and control peptides can be used for implementation of an exemplary ALISSA used to specifically detect BoNT enzymatic activity. Furthermore, the ALISSA as described herein may also be used in a column based format for use in a high-throughput system for testing large quantities of samples.Type: GrantFiled: September 14, 2020Date of Patent: March 14, 2023Assignee: CITY OF HOPEInventors: Markus Kalkum, Karine Bagramyan
-
Patent number: 11597774Abstract: Provided herein are, inter alia, compositions and methods for the treatment of cancer. The compositions include, for example, an antibody variable domain or antibody construct, inter alia, useful for targeting and killing cancer cells. Due to their ability to differentially bind cancer cells versus non-cancer cells, the compositions provided herein may be used, for example, for therapeutic and diagnostic purposes.Type: GrantFiled: May 4, 2018Date of Patent: March 7, 2023Assignees: CITY OF HOPE, BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Hong Qin, Larry W. Kwak, Guowei Wei
-
Patent number: 11591596Abstract: The present disclosure relates to a compound including a nucleic acid sequence conjugated to an anti-microRNA or a microRNA-mimic or a compound including a modified anti-microRNA sequence, compositions of such a compound, and method of treatment of a disease, and method of suppressing microRNA activity by the disclosed compound or composition.Type: GrantFiled: September 2, 2020Date of Patent: February 28, 2023Assignee: City of HopeInventors: Marcin Tomasz Kortylewski, Piotr Marek Swiderski, Guido Marcucci, Bin Zhang, Ya-Huei Kuo
-
Publication number: 20230056712Abstract: Disclosed herein are antibodies or immunogenic fragments thereof that specifically bind to Epstein-Barr virus (EBV) glycoprotein 350 (gp350) or 220 or one or more immunogenic peptides. Also disclosed are immunogenic peptides comprising fragments of gp350 amino acid sequence, EBV antibody-small molecule conjugates and pharmaceutical compositions comprising the antibody or an immunogenic fragment thereof, one or more immunogenic peptides, or the EBV antibody-small molecule conjugate. The antibodies, immunogenic peptides, conjugates, and pharmaceutical compositions can be used to treat or prevent EBV infections and EBV-associated conditions and diseases.Type: ApplicationFiled: June 16, 2022Publication date: February 23, 2023Applicant: CITY OF HOPEInventors: Javier Gordon OGEMBO, Lorraine Zvichapera MUTSVUNGUMA
-
Patent number: 11584760Abstract: Disclosed herein, inter alia, are compositions and methods of using the same for the treatment of cancer.Type: GrantFiled: September 23, 2020Date of Patent: February 21, 2023Assignees: CITY OF HOPE, THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Sangkil Nam, David Horne, Larry Eugene Overman, Brad Loertscher